Neuroscience paper retracted after colleagues object to data publication

frontiersA paper published this October in the journal Frontiers In Neuroscience was retracted the following month because the authors’ collaborators did not give them permission to publish some of the data.

The paper detailed how and why the authors use the software program Nengo to test large simulations of nervous system networks. As part of the research, the authors tested five systems, one of which they were working on with another group. Due to a “miscommunication,” the authors thought they had received permission to publish the data; they plan to resubmit a paper describing the other four systems.

Here’s the official retraction note: Continue reading Neuroscience paper retracted after colleagues object to data publication

JAMA retracts osteoporosis paper with manipulated data

Screen Shot 2015-12-29 at 10.48.49 AMA JAMA study on an inexpensive treatment for osteoporosis has been retracted because the first author falsified or fabricated data. We’ve been expecting this one: An investigation at Women’s College Hospital in Toronto, the bone researcher’s former workplace, had already revealed issues with the paper.

An internal memo sent to staff (available in full here) in October explained that the investigation had found “unequivocal evidence of systematic data manipulation” by Sophie Jamal, who had already resigned from her positions at WCH and the University of Toronto.

The study appeared to show that nitroglycerin ointment could have a small positive effect on bone mineral density in postmenopausal patients. It’s been cited 30 times, according to Thomson Scientific’s web of Knowledge. (That’s two more times than when we last reported on the paper: It was cited once by the investigation, and once by a paper that was published earlier in October, but had not yet been indexed.)

Here’s the retraction note for “Effect of Nitroglycerin Ointment on Bone Density and Strength in Postmenopausal Women: A Randomized Trial:”

Continue reading JAMA retracts osteoporosis paper with manipulated data

After lawsuit, university releases misconduct report about nutrition researcher Chandra

R K Chandra
R K Chandra, self-proclaimed father of nutritional immunology (from www.drrkchandra.com)

Memorial University in Canada has released a five-year-old report of an investigation, confirming a former nutrition professor had committed misconduct in a 2001 paper.

The 53-page report — about Ranjit Kumar Chandra, a prominent and once-lauded researcher — focuses on a Nutrition paper that examined the effectiveness of vitamins patented by Chandra. The report, authored by MUN professor emeritus William Pryse-Phillips, lists 41 problems with the paper, which it concludes:

…was not in full compliance with the scientific, ethical, and/or integrity standards of Memorial University at the time.

The paper was retracted in 2005; the report is dated 2009. We asked Pryse-Phillips why the university took so long to release it. He told us:

Continue reading After lawsuit, university releases misconduct report about nutrition researcher Chandra

Intellectual property issues sink cancer paper in JACS

176 spine minimum. full size. Editor: Lingling JEM: Leslie RTP: Michael ReidThe authors of a paper on a mechanism for potential cancer therapies are retracting it after realizing they published some proprietary findings “without permission and agreement from St. Jude Children’s Research Hospital.”

According to the retraction note in Journal of the American Chemical Society, the authors included an X-ray crystal structure and data that were gathered at St. Jude’s and considered the hospital’s intellectual property. On the paper, the last author, Zhengding Su, listed an affiliation at St. Jude and Hubei University of Technology in China, along with Amersino Biodevelop Inc., based in Waterloo, Canada.

Here’s the note for “Efficient Reactivation of p53 in Cancer Cells by a Dual MdmX/Mdm2 Inhibitor:”  Continue reading Intellectual property issues sink cancer paper in JACS

After court verdict, BMJ retracts 26-year-old paper

downloadToday, The BMJ retracted a 1989 paper about the role of breastfeeding and formula in infant eczema — 20 years after the data were called into question by a university report.

However, the report was kept secret — due, by some accounts, to alleged threats of a lawsuit. That is, until this year, when author Ranjit Kumar Chandra — who once dubbed himself the “father of nutritional immunology” — lost a $132 million libel case. That case, against the Canadian Broadcasting Company (CBC) for airing a three-part documentary series on allegations of fraud against Chandra, pushed the report by his former employer Memorial University of Newfoundland into the public domain.

At 26 years, the BMJ retraction is a runner up for the longest amount of time a journal has taken to retract a paper. (We know of another retraction that was 27 years in the making, and a scientist who requested the retraction of some passages of a 1955 article in 2007, after the article became fodder for creationists.)

Here’s the first part of the retraction note:

Continue reading After court verdict, BMJ retracts 26-year-old paper

Bone researcher manipulated data in JAMA study, says investigation

Screen Shot 2015-10-27 at 10.53.53 AMA bone researcher manipulated data in a 2011 JAMA study about an inexpensive treatment for osteoporosis. That’s the conclusion of an investigation at the researcher’s former workplace, the Women’s College Hospital in Toronto, the Toronto Star reports.

The study — led and manipulated by Sophie Jamal — followed 243 women over two years, as they applied nitroglycerin ointment once a day. The ointment is currently used to prevent chest pain and treat anal fissure pain by relaxing blood vessels; Jamal’s study concluded it could help patients with osteoporosis, too:

Among postmenopausal women, nitroglycerin ointment modestly increased [bone mineral density] and decreased bone resorption.

But even the modest effect was too good to be true. Continue reading Bone researcher manipulated data in JAMA study, says investigation

Much of preclinical research into one cancer drug is flawed, says report

elife-identity-headerA review of preclinical research of a now widely used cancer drug suggests the studies contain multiple methodology flaws and overestimate the benefits of the drug.

Specifically, the researchers found that most studies didn’t randomize treatments, didn’t blind investigators to which animals were receiving the drug, and tested tumors in only one animal model, which limits the applicability of the results. Importantly, they also found evidence that publication bias — keeping studies that found no evidence of benefit from the drug, sunitinib, out of the literature — may have caused a significant overestimation of its effects on various tumor types.

Together, these findings suggest the need for a set of standards that cancer researchers follow, the journal notes in a “digest” of the paper, published Tuesday by eLife:
Continue reading Much of preclinical research into one cancer drug is flawed, says report

Investigation ends in 6th retraction for Voinnet

PLOS PathogensA sixth paper co-authored by plant researcher Olivier Voinnet has been retracted by PLOS Pathogens “following an investigation into concerns.”

The investigation found “several band duplications” in one figure provided by fifth author, Patrice Dunoyer, who took it from “the Master thesis of a former student working under his supervision, without the prior consultation or consent of this student,” according to the notice. There was also an incorrect “loading control” in another figure, attributed to first author Raphael Sansregret and last author Kamal Bouarab. 

Voinnet and Bouarab, the study’s corresponding authors, took full responsibility for “the publication of this erroneous paper.”

Although investigators found that the raw data in the duplicated figure backed up its conclusions, “given the nature and extent of data manipulation,” the authors asked the journal to retract the paper .

Continue reading Investigation ends in 6th retraction for Voinnet

Court grants Toronto researchers review of misconduct findings

A Canadian court has granted a review of two researchers’ application to quash the findings of a university investigation that found signs of falsified data, according to the researchers’ lawyer.

Yesterday, the court ruled that the application by Sylvia Asa and her husband, Shereen Ezzat, to quash the University Health Network investigation’s findings be reviewed by a full panel of the divisional court.

That review should take place within the next few months, Brian Moher, the researchers’ attorney, told us. The pair are pleased with the outcome, Moher told Retraction Watch:

Continue reading Court grants Toronto researchers review of misconduct findings

Canadian researchers in legal battle over investigation object to third retraction

The Journal of Clinical InvestigationA third retraction — and a notice of concern — have emerged from the investigation into a husband and wife research team at the University of Toronto that found evidence of faked images and duplicated data.

The problem, according to the latest retraction note for Sylvia Asa and Shereen Ezzat, in the Journal of Clinical Investigation: Portions of the RT-PCR gels “are duplicated in this publication and in a subsequent publication.” That subsequent publication is a 2003 paper that has received a Notice of Concern from the American Journal of Pathology.

According to the retraction note, co-author Gillian E. Wu of York University signed off on the journal’s decision, but Asa, Ezzat and second author Lei Zheng dissented to the retraction. Third author Xian-Feng Zhu couldn’t be reached. Although corresponding author Asa noted that “the initial screen of these samples support the conclusions made in the paper,” the JCI made its position perfectly clear in the note:

Continue reading Canadian researchers in legal battle over investigation object to third retraction